VISTA Specific Neutra^TM Antibody Products

Product list

VISTA (V-domain Ig Suppressor of T cell Activation), also known as VSIR, is a novel inhibitory immune checkpoint protein. VISTA is expressed on the surface of the cells, such as myeloid-derived suppressor cells (MDSCs), tumor-infiltrating lymphocytes (TILs), and tumor cells. VISTA is pH selectively interacted with ligands such as PSGL-1 and VSIG3. As an immunoregulatory receptor, it plays a critical inhibitory role in regulating immune responses, particularly in solid tumor immunotherapy.

Its Gene ID is 64115, UniProtKB ID is Q9H7M9, and OMIM ID is 615608.

VISTA Signaling & Interaction & Function

VISTA is found in various tissues and in various cancers. Its expression, regulation, and function may differ in a complex way in different cancers. Here are some interactions in which VISTA may be involved:

Inhibits MyD88-dependent TLR signaling and production of proinflammatory cytokines and mediators (Fig. 1B).
Interacts with VSIG3 and subsequently suppresses T cell activation and expansion (Fig. 1C).
Binds to PSGL-1 at acidic pH with uncharacterized signaling pathways (Fig. 1D–F).
Inhibits TCR signaling and cytokine production and promotes T cell exhaustion.

Fig. 1 The expression and interaction of VISTA in different cells.¹

Clinical significance

For solid tumor immunotherapy, mAbs against VISTA with blocking or neutralizing functions are currently in preclinical or clinical trials, as listed in Table 1.
For diagnostic and prognostic research, anti-VISTA mAbs could quantify the existence of the negative immune checkpoint protein VISTA, which is a risk factor for cancer metastasis and recurrence.

Table 1 Inhibitors of VISTA currently in clinical and preclinical trials.²

Table 1 Inhibtors of VISTA currently in clinical and preclinical trials. (Wu, et al., 2021)

Creative Biolabs has always been committed to the development and manufacturing of anti-VISTA antibodies. We are here to provide you with high-quality antibody products to advance your research. If you are interested, please contact us without hesitation.

REFERENCES

Yuan, Long, et al. "VISTA: a mediator of quiescence and a promising target in cancer immunotherapy." Trends in immunology 42.3 (2021): 209-227.
Wu, Chenyang, Xin Cao, and Xiaojin Zhang. "VISTA inhibitors in cancer immunotherapy: a short perspective on recent progresses." RSC Medicinal Chemistry 12.10 (2021): 1672-1679.

Show More Close

VISTA Specific NeutraTM Antibody Products

VISTA Signaling & Interaction & Function

Clinical significance

REFERENCES

VISTA Specific Neutra^TM Antibody Products